Clinical Trial Update: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Glesatinib, Sitravatinib, or Mocetinostat in combination with Nivolumab for non-small cell lung cancer was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Glesatinib (glesatinib)
• Mocetinostat (mocetinostat)
• Sitravatinib (sitravatinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2024-04-22